Table 4 Evaluation of predictive factors for the response of radiotherapy
Variable | Univariable | multivariable | ||
|---|---|---|---|---|
OR (95% CI) | P value | OR (95% CI) | P value | |
Age (years) | 1.02 (0.97–1.07) | 0.497 | ||
Sex (female) | 1.02 (0.32–3.32) | 0.969 | ||
Duration of GO | 1.01 (0.99–1.02 | 0.500 | ||
Duration of GD | 1.00 (1.00–1.01) | 0.378 | ||
Smoking | 0.748 | |||
Current smoker | 1.0 | |||
Ex-smoker | 0.74 (0.10–5.49) | |||
Never-smoked | 0.55 (0.10–2.94) | |||
Family history of GO (yes) | 1.6 (0.44–5.78) | 0.473 | ||
Previous use of high-dose IV steroid (yes) | 2.80 (0.83–9.40) | 0.096 | 1.80 (0.208–15.484) | 0.594 |
Concurrent oral steroid use during radiotherapy (yes) | 3.75 (1.11–12.65) | 0.033 | 0.99 (0.156–6.292 | 0.921 |
Radioiodine therapy (yes) | 1.05 (0.10–10.84) | 0.970 | ||
Thyroidectomy (yes) | 0.45 (0.11–1.86) | 0.270 | ||
Treatment phase (late) | 0.55 (0.17–1.76) | 0.317 | ||
TSH (uIU/mL) | 1.14 (0.83–1.57) | 0.420 | ||
free T4 (ng/dL) | 0.69 (0.27–1.81) | 0.459 | ||
Initial TBII (IU/L) | 1.02 (0.97–1.07) | 0.403 | ||
TBII change (IU/L) | 0.99 (0.95–1.02) | 0.966 | ||
CAS | 1.36 (0.96–1.92) | 0.079 | 1.28 (0.76—2.14) | 0.355 |
degree of proptosis (mm) | 0.99 (0.83–1.17) | 0.901 | ||
Diplopia (Gorman score) | 0.564 | |||
absent | 1.0 | |||
Intermittent | 2.67 (0.42–16.83) | |||
Inconstant | 2.40 (0.46–12.61) | |||
constant | 3.20 (0.58–17.72) | |||
EOM movement ≤30° | 5.63 (1.56–20.31) | 0.008 | 5.13 (1.25–21.14) | 0.043 |
MRD1 (mm) | 1.00 (0.69–1.46) | 0.999 | ||
PFH (mm) | 1.02 (0.79–1.33) | 0.863 | ||
VA, logMAR | 7.64 (1.56–37.47) | 0.012 | 4.32 (0.54–34.55) | 0.168 |
IOP (mmHg) | 1.07 (0.89–1.29) | 0.464 | ||
Sum of EOMs (cm3) | 1.18 (0.99–1.41) | 0.050 | 3.68 (1.22–11.11) | 0.021 |
Orbital fat (cm3) | 1.16 (0.93–1.46) | 0.193 | ||